Explore tesamorelin calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.
Anonymized tesamorelin calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.
Tesamorelin is a growth-hormone-releasing-hormone (GHRH) analog most often sourced for research into visceral-fat reduction and the GH/IGF-1 axis. It is the same molecule sold as the FDA-approved drug Egrifta, and ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
Tesamorelin binds the GHRH receptor on pituitary somatotrophs to stimulate pulsatile release of endogenous growth hormone. Unlike recombinant hGH, this preserves the physiologic GH pulse pattern and the downstream IGF-1 feedback loop, which is associated with a different visceral-adiposity profile than direct hGH replacement.
The pivotal Phase 3 trials (Falutz et al., NEJM 2007; Stanley et al., JAMA 2014) demonstrated ~15–18% reductions in visceral adipose tissue at 26 weeks in HIV-associated lipodystrophy.[2] Ongoing investigator-initiated work has extended tesamorelin into non-HIV NAFLD/MASLD populations.[3]
FDA-approved as Egrifta (HIV-associated lipodystrophy). Off-label and research-grade use are outside the labeled indication.
Tesamorelin has a reported half-life of ~26–38 min. The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. Very short half-life. Tesamorelin acts as a pulse that triggers an endogenous GH release; there is no plasma buildup, so timing (typically bedtime) matters more than steady-state level. Pharmacokinetic source: FDA label (Egrifta). It is catalogued under Weight Loss on WPA.
12,308 Tesamorelin reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
WPA Analysis
Tesamorelin (trade name EGRIFTA) is the only GHRH analog in this family that holds an active FDA approval, and the trial program behind it is the most clinically substantive on this site outside the GLP-1 group. Theratechnologies developed tesamorelin specifically to treat HIV-associated lipodystrophy — the abnormal central / visceral fat accumulation that became a hallmark of long-term antiretroviral therapy — and the pivotal evidence is anchored by the Falutz et al. Phase III trial (New England Journal of Medicine, 2007), which enrolled 412 adults with HIV-associated abdominal fat accumulation and randomized them 2:1 to tesamorelin 2mg subcutaneously once daily or placebo for 26 weeks. The active arm produced a roughly 15% reduction in visceral adipose tissue on CT imaging, alongside meaningful drops in triglycerides and a small rise in IGF-1 — the result that supported FDA approval in November 2010 at the labeled 2mg/day subcutaneous dose. The molecule itself is a stabilized GHRH (1-44) analog with a trans-3-hexenoyl moiety on the N-terminus that protects it from rapid DPP-IV degradation, giving it a clinically useful subcutaneous half-life and the kind of clean GHRH-receptor selectivity that produces a physiologic, pulsatile GH release rather than the flattened exposure a long-acting analog would create. That 44-amino-acid length is structurally significant: native endogenous human GHRH is itself a 44-amino-acid peptide (GHRH 1-44 amide), which makes tesamorelin the only GHRH analog in the modern peptide research market that preserves the full-length sequence of the endogenous signaling peptide. Sermorelin is GHRH (1-29) — truncated at the 29th residue, missing the entire C-terminal 15-amino-acid tail — and CJC-1295 No DAC is built on that same 29-amino-acid backbone with four substituted residues added for DPP-IV stability. Both are partial sequences. Tesamorelin engages the GHRH receptor with the same complete amino-acid footprint the body already uses, and that structural completeness is the most plausible explanation for why tesamorelin is the only member of this analog family to have earned an FDA approval — and likely why its clinical outcomes in the Falutz program were compelling enough to support one.
Tesamorelin's labeled cadence is once daily, every day, and the labeled dose is the single 2mg figure — Phase III did not evaluate a higher arm, and the more recent EGRIFTA SV reformulation (2019, FDA) was a delivery-and-stability change rather than a new dose.
Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.
WPA DOSING INSIGHT
The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.
WPA RECONSTITUTION INSIGHT
Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.